# Eli Lilly Q2 2026 earnings and revenue surge

> Live situation record from CLSTR: https://clstr.news/situations/eli-lilly-q2-2026-earnings-surge
> Updated: 2026-08-04T19:48:53.000Z. Sources: 21. Developments: 2.

Eli Lilly’s shares rose modestly on July 28, 2026 after analysts lifted price targets ahead of its earnings release. The company posted Q2 2026 non‑GAAP earnings of $8.38 per share, well above the $6.07 consensus, and revenue of about $23 billion – a 48 % year‑over‑year increase driven by its obesity‑treatment portfolio. Sales of the diabetes drug Mounjaro jumped 91 % to $9.9 billion and the weight‑loss drug Zepbound grew 44 % to $4.9 billion, together accounting for roughly two‑thirds of quarterly revenue. Worldwide realized prices for the GLP‑1 medicines fell 13 % (3 % in the United States, 36 % outside) after Mounjaro entered China’s national reimbursement list. Adjusted net income rose 32 % to $7.5 billion, prompting Lilly to raise its full‑year 2026 revenue outlook to $85‑$87 billion and reaffirm its EPS target. In the same quarter Lilly launched an oral obesity pill, Foundayo, which generated $98 million in sales, short of the $105.6 million analysts had expected.

## Claims

- Eli Lilly's second‑quarter 2026 revenue was $23 billion, up 48 percent year over year. (corroborated by 7 sources)
- Mounjaro sales were $9.9 billion, up 91 percent year over year. (corroborated by 7 sources)
- Zepbound sales were $4.9 billion, up 44 percent year over year. (corroborated by 7 sources)
- Obesity drugs accounted for about two‑thirds of Eli Lilly's quarterly revenue. (corroborated by 7 sources)
- Eli Lilly raised its full‑year 2026 revenue forecast to $85‑87 billion. (corroborated by 6 sources)

## Timeline

### 2026-08-04: Eli Lilly Q2 Revenue Jumps 48% on Obesity Drug Sales

Eli Lilly’s Q2 revenue hit $23 billion, up 48%, led by Mounjaro ($9.9 bn) and Zepbound ($4.9 bn); obesity drugs now make up about two‑thirds of sales, prices fell 13% globally, and the full‑year outlook was nud

19 sources. https://clstr.news/cluster/eli-lilly-and-tat-technologies-report-strong-q2-2026-earnings

### 2026-07-28: Eli Lilly shares rise 2.1% on analyst upgrades; MercadoLibre to report Q2 2026 earnings; Elicio Therapeutics forecasts a

Eli Lilly shares rose 2.1% as analysts lifted price targets; MercadoLibre will release Q2 2026 results on Aug 5; Elicio Therapeutics forecasts a Q2 2026 loss of $0.53 per share.

4 sources. https://clstr.news/cluster/institutional-investors-adjust-stakes-in-elevance-health-and-tesla

---
Cite as: Eli Lilly Q2 2026 earnings and revenue surge. CLSTR, https://clstr.news/situations/eli-lilly-q2-2026-earnings-surge